NORTH west companies involved in the biotechnology and healthcare sectors are among those eyeing floats on the Alternative Investment Market but are likely to delay any moves until next year, the London Stock Exchange's chief executive told the M.E.N. during a visit to Manchester.

Xavier Rolet said talks were underway with several firms in the region, which he hailed for its record in innovation and entrepreneurial spirit.

He met advisers, brokers and bosses of a number of AIM-listed companies before visiting the headquarters of biotech firm Epistem.

He said some of the biggest issues faced by businesses on AIM include the need for more liquidity to help them raise funds, and the need for more tax incentives for people and institutions investing in equities, in particular for venture capital trusts.

AIM is home to around 1,450 companies, of which 1,156 are based in the UK and employ over 250,000 people.